Form 4: Nektar Therapeutics Executive Jonathan Zalevsky Sells Shares to Cover Tax Obligations

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 7,355 shares of common stock on May 17, 2024, to cover tax withholding obligations related to vesting RSUs.

Summary

• On May 17, 2024, Jonathan Zalevsky, the Chief R&D Officer of Nektar Therapeutics, sold 7,355 shares of the company's common stock.
• The sale was executed to cover required tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $1.75, with individual transactions ranging from $1.72 to $1.80.
• Following the transaction, Zalevsky directly owns 257,670 shares of Nektar Therapeutics.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive's stock sale for tax purposes, which is neither particularly positive nor negative.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax obligations. Monitoring these transactions can provide insights into management's perspective on the company's value, although sales for tax purposes are generally less informative.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but the effect is likely minimal given the relatively small number of shares sold.

Key Dates